Allarity Therapeutics, Inc..
ALLR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments. The company utilizes its proprietary DRP® companion diagnostic platform to identify patients most likely to respond to its drug candidates. Allarity's pipeline includes sten...Show More
Better Health for All
20
Allarity Therapeutics is a clinical-stage pharmaceutical company entirely devoted to developing personalized cancer treatments, which aims to deliver exceptional health benefits for cancer patients. The company is conducting Phase 2 clinical trials for stenoparib, a drug candidate for advanced ovarian cancer.
1
An ongoing Phase 2 study has shown durable clinical benefit and good tolerability for stenoparib.
2
A new Phase 2 trial for stenoparib in advanced ovarian cancer enrolled its first patient on June 2, 2025, and a second patient has been dosed.
3
The company's core business is research and development for these treatments, indicating significant investment in health innovation.
Fair Money & Economic Opportunity
0
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing cancer treatments.
1
The company's core business does not involve lending, insuring, moving, or storing money for consumers.
2
As such, the ethical value 'Fair Money & Economic Opportunity' and its associated KPIs, which are designed for financial institutions, are not applicable. The provided articles contain no data relevant to metrics such as underserved clients, pricing fairness, exploitative fees, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion, or product simplicity for financial products.
3
Fair Pay & Worker Respect
10
The CEO's salary is $849,086, while the average annual employee salary is $109,689, resulting in a pay ratio of approximately 7.74:1.
1
The company has implemented warrant programs as an incentive for board members, employees, and key persons.
2
As of December 31, 2024, the company had 7 employees (6 full-time, 1 half-time), none of whom are represented by labor unions or covered by collective bargaining agreements.
3
The company considers its relationship with its employees to be good.
4
No information is available regarding living wage coverage, safety incident rates, pay equity ratios, worker engagement scores, turnover rates, labor violation incidents, insecure contract share, or health insurance coverage for the general workforce.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Allarity Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-30
Allarity Therapeutics settled an SEC investigation in 2025 with a $2.5 million civil penalty.
1
The company also identified material weaknesses in internal controls over financial reporting, leading to restatements of prior period financial statements.
2
A Code of Ethics and Business Conduct has been published, outlining policies for honest conduct, conflicts of interest, and compliance.
3
This code includes reporting lines for employees and directors, including the Audit Committee and Chief Financial Officer, and explicitly prohibits retaliation against those reporting misconduct.
4
However, details on the strength and enforcement of the anti-corruption policy, such as training frequency or due diligence processes, are not provided.
5
Kind to Animals
0
No information relevant to the 'Kind to Animals' ethical value was found in the provided article.
1
The article focuses solely on an internal personnel change within Allarity Therapeutics, Inc. and does not contain any data regarding animal testing, cruelty-free certifications, animal-derived ingredients, or conservation efforts.
2
No War, No Weapons
0
No evidence available to assess Allarity Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
The provided article, a summary of the company's annual reports, explicitly states that it does not contain detailed sustainability information, quantitative data, or specific metrics relevant to planet-friendly business.
1
Therefore, no evidence was found to assess the company against any of the specified KPIs.
2
Respect for Cultures & Communities
0
The provided articles focus on Allarity Therapeutics' corporate and financial news, clinical trials, patent filings, legal matters, and research collaborations.
1
No specific, concrete data points or information related to formal partnerships with indigenous or local community groups, revenue reinvested in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment, grievance mechanisms, community complaint resolution, FPIC processes, community governance inclusion, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license to operate, charitable giving to cultural organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training were found.
2
Safe & Smart Tech
0
Allarity Therapeutics collects data only for the purpose of the service, such as press release distribution and application submissions.
1
It retains application data for 1 year and unsolicited application data for up to 6 months, requiring consent to keep unsolicited applications on record.
2
The company also mentions GDPR compliance for application submissions.
3
Zero Waste & Sustainable Products
0
No specific data for ALLR.US regarding waste diversion rates, product recyclability, packaging sustainability, recycled content percentage, single-use plastic reduction, take-back program coverage, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability score, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education was found in the provided articles.
1
The articles discuss general sustainability trends and challenges within the pharmaceutical industry but do not offer concrete, company-specific metrics for Allarity Therapeutics, Inc.
2